1. Home
  2. ADUS vs ZYME Comparison

ADUS vs ZYME Comparison

Compare ADUS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$113.08

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$27.06

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADUS
ZYME
Founded
1979
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
ADUS
ZYME
Price
$113.08
$27.06
Analyst Decision
Buy
Strong Buy
Analyst Count
11
10
Target Price
$138.73
$30.67
AVG Volume (30 Days)
174.5K
963.2K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
6.76
N/A
EPS
4.66
N/A
Revenue
$1,346,596,000.00
$134,481,000.00
Revenue This Year
$25.50
$64.45
Revenue Next Year
$7.11
$67.04
P/E Ratio
$24.21
N/A
Revenue Growth
18.77
116.21
52 Week Low
$88.96
$9.03
52 Week High
$136.72
$28.49

Technical Indicators

Market Signals
Indicator
ADUS
ZYME
Relative Strength Index (RSI) 46.29 65.59
Support Level $110.07 $24.88
Resistance Level $116.00 $26.55
Average True Range (ATR) 2.92 1.13
MACD -0.27 -0.21
Stochastic Oscillator 26.27 84.07

Price Performance

Historical Comparison
ADUS
ZYME

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: